Investigating the role of a peptide in obesity and insulin resistance
Endothelin-1 in Obesity and Insulin Resistance
This study is looking at how a substance called endothelin-1 might make it harder for your body to use insulin properly, which can lead to type II diabetes, especially in people who are overweight, and it hopes to find out if blocking certain receptors can help improve insulin sensitivity and blood sugar levels.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi Med Ctr NIH-funded |
| Lab location | 1 site (Jackson, United States) |
| Project ID | NIH-11018503 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific peptide, endothelin-1 (ET-1), contributes to insulin resistance, a condition that often leads to type II diabetes and is prevalent in individuals with obesity. The study examines the mechanisms by which ET-1 affects insulin signaling in adipose tissue, particularly how it interacts with different receptors. By using animal models, researchers aim to determine if blocking certain receptors can improve insulin sensitivity and blood glucose levels, potentially leading to new treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who are obese and experiencing insulin resistance or related metabolic issues.
Not a fit: Patients who are not obese or do not have insulin resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve insulin sensitivity and help manage obesity-related conditions.
How similar studies have performed: Previous studies have shown that targeting similar pathways in insulin resistance has led to promising results, indicating that this approach may be effective.
Where this research is happening
Jackson, United States
- University of Mississippi Med Ctr — Jackson, United States (Active)
Researchers
- Principal investigator: Speed, Joshua S — University of Mississippi Med Ctr
- Study coordinator: Speed, Joshua S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.